• 24325 Citations
  • 82 h-Index
1975 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Peter J Houghton is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Age-associated genes in human mammary gland drive human breast cancer progression

Gu, X., Wang, B., Zhu, H., Zhou, Y., Horning, A. M., Huang, T. H. M., Chen, Y., Houghton, P., Lai, Z., Michalek, J. E. & Sun, L. Z., Jun 15 2020, In : Breast Cancer Research. 22, 1, 64.

Research output: Contribution to journalArticle

Open Access
  • Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway

    VanCleave, A., Palmer, M., Fang, F., Torres, H., Rodezno, T., Li, Q., Fuglsby, K., Evans, C., Afeworki, Y., Ross, A., Rao, P., Leiferman, P., Zheng, S., Houghton, P. & Tao, J., Jul 1 2020, In : Oncotarget. 11, 27, p. 2597-2610 14 p.

    Research output: Contribution to journalArticle

    Open Access
  • Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium

    Gill, J., Zhang, W., Zhang, Z., Roth, M., Harrison, D. J., Rowshan, S., Erickson, S., Gatto, G., Kurmasheva, R., Houghton, P., Teicher, B., Smith, M. A., Kolb, E. A. & Gorlick, R., 2020, (Accepted/In press) In : Pediatric Blood and Cancer.

    Research output: Contribution to journalArticle

  • Evaluation of eribulin combined with irinotecan for treatment of pediatric cancer xenografts

    Robles, A. J., Kurmasheva, R. T., Bandyopadhyay, A. M., Phelps, D. A., Erickson, S. W., Lai, Z., Kurmashev, D., Chen, Y., Smith, M. A. & Houghton, P. J., Jun 15 2020, In : Clinical Cancer Research. 26, 12, p. 3012-3023 12 p.

    Research output: Contribution to journalArticle

  • Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium

    Kurmasheva, R. T., Bandyopadhyay, A., Favours, E., Pozo, V. D., Ghilu, S., Phelps, D. A., McGeehan, G. M., Erickson, S. W., Smith, M. A. & Houghton, P. J., Jul 1 2020, In : Pediatric Blood and Cancer. 67, 7, e28284.

    Research output: Contribution to journalArticle

  • Press / Media

    2019 election results

    Peter J Houghton

    2/27/202/28/20

    2 items of Media coverage

    Press/Media: Press / Media

    Neuroscientist Susan Amara Named AAAS President-Elect

    Peter J Houghton

    1/28/20

    1 item of Media coverage

    Press/Media: Press / Media

    UF researchers discover breakthrough anticancer drug

    Robert A Hromas & Peter J Houghton

    1/2/20

    1 item of Media coverage

    Press/Media: Press / Media

    Leukemia, lymphoma squarely in sights of new class of drugs

    Robert A Hromas & Peter J Houghton

    12/6/1912/9/19

    7 items of Media coverage

    Press/Media: Press / Media

    Team Develop Drugs To Fight Leukemia and Lymphoma

    Robert A Hromas & Peter J Houghton

    12/9/19

    1 item of Media coverage

    Press/Media: Press / Media